Approaches for generation of anti-leukemia specific T cells.
Cell Regen
; 7(2): 40-44, 2018 Dec.
Article
en En
| MEDLINE
| ID: mdl-30671229
ABSTRACT
As three decades ago, it was reported that adoptive T cell immunotherapy by infusion of autologous tumor infiltrating lymphocytes (TILs) mediated objective cancer regression in patients with metastatic melanoma. A new era of T cell immunotherapy arose since the improvement and clinical use of anti-CD19 chimeric antigen receptor T cells (CAR-T) for the treatment of refractory and relapsed B lymphocyte leukemia. However, several challenges and difficulties remain on the way to reach generic and effective T cell immunotherapy, including lacking a generic method for generating anti-leukemia-specific T cells from every patient. Here, we summarize the current methods of generating anti-leukemia-specific T cells, and the promising approaches in the future.
ACT, adoptive cellular immunotherapy; APL, promyelocytic leukemia; Anti-leukemia T cell; B-ALL, cell acute lymphoblastic leukemia; CAR-T; CAR-T, chimeric antigen receptor T cells; CML, chronic myelogenous leukemia; CR, complete remission; CTLs, cytotoxic T cells; DLI, donor lymphocyte infusion; FLT3-ITD, FLT3 internal tandem duplication; GVHD, graft-versus-host disease; GVL, graft-versus-leukemia; HLA, human leukocyte antigen; HPCs, hematopoietic progenitor cells; IL-2, interleukin-2; Ig, immunoglobulin; T cell immunotherapy; T cell reprogramming; TAA, tumor-associated antigen; TCR-T; TCR-T, TCR gene-modified T cell; TIL, infiltrating lymphocytes; TKI, tyrosine kinase inhibitor; WT1, Wilm's tumor antigen 1; allo-HSCT, allogeneic hematopoietic stem cell transplantation; hESC, human embryonic stem cell; iPSCs, induced pluripotent stem cells; iTs, induced functional T cells; scFv, single-chain variable fragment
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Cell Regen
Año:
2018
Tipo del documento:
Article
País de afiliación:
China